Seven Life Science Park Companies Receive Changping District 'Technology Vice President' Special Fund Support

CHIGENOVO is a national high-tech enterprise specializing in the development of gene therapy drugs for hereditary eye diseases and clinical gene diagnosis, and is one of the first companies in China to establish a presence in this field.The company is committed to gene technology innovation, eliminating hereditary eye diseases, and providing "one-stop" solutions for precise diagnosis and treatment for patients with hereditary eye diseases.

CHIGENOVO Co., Ltd. has established a genetic eye disease database and a specialized disease cohort through its clinical gene diagnosis platform, summarizing the gene mutation spectrum and mutation hotspots in Chinese patients to provide therapeutic targets for subsequent gene therapy drug development. On this basis, the company is developing drugs with independent intellectual property rights, including gene replacement therapy and gene editing therapy, striving to achieve a "from zero to one" breakthrough. A complete drug development system has been established, encompassing target screening, basic research, animal experimental validation, stem cell validation, AAV virus research and production, clinical trial operations, and drug registration applications.

AcepBio is committed to discovering and developing disruptive conjugate drugs, with PDC (Peptide Drug Conjugates) as its primary focus.The company is the first biotechnology enterprise in China to engage in the research and development of self-assembling nano-biomedicines, bringing a completely new breakthrough in conjugate drug design; its core technology lies in the self-developed underlying design capability for self-assembling conjugate drugs and a drug development platform. The project's features include the transformation from the National Center for Nanoscience, relying on the key laboratories of the National Medical Products Administration and the Chinese Academy of Sciences, with rich experience in early R&D transformation. It has influence in the nanomedicine transformation industry and quickly advances disruptive conjugate drugs to clinical transformation through world-first new drug creation technologies, addressing unmet clinical needs and serving patients worldwide.

CHIGENOVO is an innovative high-tech enterprise born under the broad context of precision medicine.The company adheres to the strategy of domestically produced autonomy, using NGS as the underlying technology. It focuses on three major business directions—medicine, science and technology, and health—and relies on an intelligent platform covering the entire process. The company has developed three comprehensive solutions: NGS clinical applications, NGS research, and precision medical services, committing to a development path from scientific research to clinical transformation and ultimately to serving everyone.

The group and its subsidiaries have been awarded as national high-tech enterprises and specialized, refined, novel "little giant" enterprises, successively establishing several scientific research platforms such as an academician expert workstation, a postdoctoral research workstation, and a gene detection in vitro diagnostic reagent engineering technology research center.

Bohui Innovation has a 40,000-square-meter comprehensive R&D center and is a high-tech biomedical enterprise integrating R&D, production, sales, and after-sales service.Relying on strong independent research and development capabilities, the company has established a professional R&D team. Through continuous technological innovation, it has formed five major technology platforms: molecular diagnostics, immunoassays, atomic absorption, atomic fluorescence, and mass spectrometry. It has successfully industrialized products from these technology platforms. The human trace element detection system has been widely applied in over 7,000 hospitals across China, with an annual testing volume of up to 22 million people. The fully automated nucleic acid detection system, developed using advanced microfluidic chip technology and known as a "lab-on-a-chip," serves a wide range of medical and health institutions.

Wantai Bio is a high-tech enterprise engaged in the research, development, and production of biological diagnostic reagents and vaccines.The company is committed to "contributing to the health cause of humanity," and is dedicated to transforming biotechnological achievements into high-quality products to serve the public. The company has seven subsidiaries, with products covering multiple fields including enzyme immunoassays, colloidal gold, chemiluminescence, nucleic acid testing, biochemistry, vaccines, and quality control materials.

CHIGENOVO Co., Ltd. places great emphasis on the construction of its scientific research team and R&D platform. It already possesses hundreds of technical professionals with expertise in various fields, as well as technology platforms specializing in enzyme immunoassays, chemiluminescence, rapid diagnostics, nucleic acid testing, virus isolation and large-scale cultivation, genetic engineering, preparation of monoclonal and polyclonal antibodies, and large-scale purification.

With strong technical strength and quick market responsiveness, the company has met clinical and disease surveillance needs during each major infectious disease outbreak in China, such as SARS, H5N1 avian influenza, influenza A, and EV71 hand-foot-mouth disease.

As an innovative enterprise in the digital management of chronic respiratory diseases, DaoBo Medical is committed to building a specialized medical service ecosystem for circulation, respiration, and sleep by integrating intelligent chronic disease management platforms, digital healthcare, and clinical decision support for specific diseases, leveraging AI, large language models, and innovative intelligent home medical devices.

The company has developed an innovative model of "Physician Group + Internet Healthcare" to connect patient data both inside and outside the hospital, vertically integrating homogenized specialist resources in respiratory medicine. This significantly improves patients' access to premium healthcare resources. Through software-driven, clinically validated interventions such as "Digital Therapeutics," the company provides innovative diagnostic and treatment solutions for patients with respiratory and related diseases. It also offers specialized disease solutions to grassroots communities and secondary/tertiary medical institutions, including clinical decision support systems, disease-specific quality control platforms, and teleconsultation systems.

CHIGENOVO has successively developed hundreds of products in the "Guozhen," "Xianglange," and "Zhuzhen" series, owns 1 CNAS nationally accredited laboratory, and has participated in undertaking key national R&D projects and National Natural Science Foundation projects.Through independent research and development and technological innovation protection, a large number of scientific and technological achievements with independent intellectual property rights have been formed, and multiple patents, software copyrights, and registered trademarks have been applied for and obtained.

The company adheres to independent innovation and industry-university-research cooperation, continuously strengthening technical exchanges and collaboration to steadily enhance its overall scientific research capabilities. Currently, it has engaged in various forms of cooperation with dozens of research institutions both in China and abroad, including Peking University, Zhejiang University, Jiangnan University, Beijing University of Chinese Medicine, the China Academy of Chinese Medical Sciences, and the China National Research Institute of Food and Fermentation Industries, exploring new models for industry-university-research collaboration and the transformation of scientific and technological achievements.